News

Targeting a membrane protein called TMEM16F may help reduce the spread of toxic clumps, or aggregates, of alpha-synuclein — a hallmark of Parkinson’s disease — across the brain, according to a new study by a team in Israel. The scientists found that a genetic variant of the TMEM16F gene…

Vivolta and Neurochase have partnered to manufacture specialized micro-catheters using the former’s medical electrospinning  (MediSpin) technology to deliver therapies directly to specific brain regions for neurological conditions like Parkinson’s disease. The technology would enhance Neurochase’s Convection Enhanced Delivery (CED) system, which is designed to allow…

An investigational treatment for Parkinson’s disease known as GT-02287 safely led to a roughly 53% increase in GCase enzyme activity, as measured in dried blood spots from treated healthy adults relative to those given a placebo in a Phase 1 clinical trial, its developer, Gain Therapeutics, reported. This…

People with Parkinson’s face risks during hospital stays, even when admitted for reasons other than the neurodegenerative disease itself, leading researchers to urge hospitals and health systems to adopt better practices, such as those recommended by the Parkinson’s Foundation. “Patients with Parkinson’s disease are at increased risk for…

ACI-7104, an investigational vaccine to treat people in the early stages of Parkinson’s disease, is showing safety and tolerability in a Phase 2 clinical trial, while also inducing the production of anti-alpha-synuclein antibodies at high levels, according to interim trial findings. Being developed by AC Immune,…

Crushed dried seeds of the jujube fruit, a traditional herbal medicine also known as Chinese or red date, eased the motor symptoms of Parkinson’s and helped with neurogenesis, the process by which new neurons are formed in the brain, in a mouse model of the disease. In a study led…

Vesalius Therapeutics has entered into an agreement with GSK to advance the development of new therapies for Parkinson’s disease and one other undisclosed neurodegenerative condition. Under the agreement, Vesalius will be responsible for identifying new treatment targets for the conditions, while GSK will have the option to…

The Critical Path Institute (C-Path) is launching a new initiative to advance research on how Parkinson’s disease impacts women and people across the gender spectrum. The goal is to develop treatments and technologies that take into account each person’s unique experience with the disease, leading to more equitable approaches for…

Higher levels of proteins called chaperones are linked with lower levels of disease-driving toxic protein clumps in the brains of people with Parkinson’s disease, a new study shows. The findings suggest that increasing chaperone proteins may be a viable therapeutic strategy for Parkinson’s. Data from the study also revealed…

Researchers have developed a method to detect clumps of alpha-synuclein protein, a hallmark of Parkinson’s disease, within extracellular vesicles (EVs) purified from blood, providing a possible aid to Parkinson’s diagnosis before symptoms appear. EVs are tiny membrane-bound sacs released from cells that can carry a variety of molecules, including…